Study limitation: The fatigue finding is a secondary outcome with a borderline p-value (0.041) from an open-label trial — potential placebo effect cannot be excluded despite biological plausibility from MTX-PG data | ReachRx
Effect of different folic acid doses on methotrexate-related toxicity and its association with erythrocyte methotrexate-polyglutamates in patients with rheumatic diseases: a single-center exploratory randomized controlled trial
Study limitation reported by the research below: “The fatigue finding is a secondary outcome with a borderline p-value (0.041) from an open-label trial — potential placebo effect cannot be excluded despite biological plausibility from MTX-PG data.”
